Investigators Hope to Build on Early Efficacy in KRAS G12C-Mutated CRC

Investigators have explored the potential of KRAS inhibition in patients with colorectal cancer (CRC), and early results have established the pathway as a prime target for drug development. For example, sotorasib (Lumakras) monotherapy and adagrasib (MRTX849) alone or in combination with cetuximab (Erbitux) can inhibit KRAS, long thought to be an “undruggable” target.